SEARCH

SEARCH BY CITATION

References

  • 1
    Simmonds P. Viral heterogeneity of the hepatitis C virus. J Hepatol 1999; 31(Suppl. 1): 5460.
  • 2
    Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 55662.
  • 3
    Farci P, Purcell RH. Clinical significance of hepatitis C virus genotypes and quasispecies. Semin Liver Dis 2000; 20: 10326.
  • 4
    Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29(Suppl. 1): 7481.
  • 5
    World Health Organization. Hepatitis C–global prevalence (update). Wkly Epidemiol Rec 1999;74:4257.
  • 6
    Angelico M, Renganathan E, Gandin C, et al. Chronic liver disease in the Alexandria governorate, Egypt: contribution of schistosomiasis and hepatitis virus infections. J Hepatol 1997; 26: 23643.
  • 7
    Madhava V, Burgess C, Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis 2002; 2: 293302.
  • 8
    Abdulkarim AS, Zein NN, Germer JJ, et al. Hepatitis C virus genotypes and hepatitis G virus in hemodialysis patients from Syria: identification of two novel hepatitis C virus subtypes. Am J Trop Med Hyg 1998; 59: 5716.
  • 9
    Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011; 31(Suppl. 2): 6180.
  • 10
    Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011; 31(Suppl. 2): 3060.
  • 11
    Nguyen MH, Keeffe EB. Chronic hepatitis C: genotypes 4 to 9. Clin Liver Dis 2005; 9: 41126, vi.
  • 12
    Nicot F, Legrand-Abravanel F, Sandres-Saune K, et al. Heterogeneity of hepatitis C virus genotype 4 strains circulating in south-western France. J Gen Virol 2005; 86(Pt 1): 10714.
  • 13
    Schroter M, Zollner B, Schafer P, et al. Epidemiological dynamics of hepatitis C virus among 747 German individuals: new subtypes on the advance. J Clin Microbiol 2002; 40: 18668.
  • 14
    Matera G, Lamberti A, Quirino A, et al. Changes in the prevalence of hepatitis C virus (HCV) genotype 4 in Calabria, Southern Italy. Diagn Microbiol Infect Dis 2002; 42: 16973.
  • 15
    Argentini C, Dettori S, Villano U, et al. Molecular characterisation of HCV genotype 4 isolates circulating in Italy. J Med Virol 2000; 62: 8490.
  • 16
    Sanchez-Quijano A, Abad MA, Torronteras R, et al. Unexpected high prevalence of hepatitis C virus genotype 4 in Southern Spain. J Hepatol 1997; 27: 259.
  • 17
    Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. Genetic epidemiology of hepatitis C virus throughout egypt. J Infect Dis 2000; 182: 698707.
  • 18
    Shobokshi OA, Serebour FE, Skakni L, Al-Saffy YH, Ahdal MN. Hepatitis C genotypes and subtypes in Saudi Arabia. J Med Virol 1999; 58: 448.
  • 19
    Ramia S, Koussa S, Taher A, et al. Hepatitis-C-virus genotypes and hepatitis-G-virus infection in Lebanese thalassaemics. Ann Trop Med Parasitol 2002; 96: 197202.
  • 20
    Njouom R, Pasquier C, Ayouba A, et al. High rate of hepatitis C virus infection and predominance of genotype 4 among elderly inhabitants of a remote village of the rain forest of South Cameroon. J Med Virol 2003; 71: 21925.
  • 21
    Oni AO, Harrison TJ. Genotypes of hepatitis C virus in Nigeria. J Med Virol 1996; 49: 17886.
  • 22
    Xu LZ, Larzul D, Delaporte E, Brechot C, Kremsdorf D. Hepatitis C virus genotype 4 is highly prevalent in central Africa (Gabon). J Gen Virol 1994; 75: 23938.
  • 23
    Singh S, Malhotra V, Sarin SK. Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in India. Indian J Med Res 2004; 119: 1458.
  • 24
    Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798801.
  • 25
    Liu CH, Kao JH. Interleukin-28B genetic variations and response to interferon-based therapy: Asian perspectives. J Gastroenterol Hepatol 2011; 26: 134853.
  • 26
    Ochi H, Maekawa T, Abe H, et al. IL-28B predicts response to chronic hepatitis C therapy–fine-mapping and replication study in Asian populations. J Gen Virol 2011; 92(Pt 5): 107181.
  • 27
    Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 1209 e18.
  • 28
    Asselah T, De Muynck S, Broet P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2012; 56: 52732.
  • 29
    Martial J, Morice Y, Abel S, et al. Hepatitis C virus (HCV) genotypes in the Caribbean island of Martinique: evidence for a large radiation of HCV-2 and for a recent introduction from Europe of HCV-4. J Clin Microbiol 2004; 42: 78491.
  • 30
    Raghuraman S, Abraham P, Sridharan G, Daniel HD, Ramakrishna BS, Shaji RV. HCV genotype 4–an emerging threat as a cause of chronic liver disease in Indian (south) patients. J Clin Virol 2004; 31: 2538.
  • 31
    Chaix ML, Serpaggi J, Batisse D, et al. Phylogenetic analysis reveals a cluster of genotype 4 HCV transmitted by sexual intercourse in HIV-1 infected men. Hepatology 2004; 4: 177A.
  • 32
    Gane EJ, Naoumov NV, Williams R. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 335: 5223.
  • 33
    Khan MH, Farrell GC, Byth K, et al. Which patients with hepatitis C develop liver complications? Hepatology 2000; 31: 51320.
  • 34
    Zekry A, Whiting P, Crawford DH, et al. Liver transplantation for HCV-associated liver cirrhosis: predictors of outcomes in a population with significant genotype 3 and 4 distribution. Liver Transpl 2003; 9: 33947.
  • 35
    Wali MH, Heydtmann M, Harrison RF, Gunson BK, Mutimer DJ. Outcome of liver transplantation for patients infected by hepatitis C, including those infected by genotype 4. Liver Transpl 2003; 9: 796804.
  • 36
    Roulot D, Bourcier V, Grando V, et al. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 2007; 14: 4607.
  • 37
    Abdel-Hamid M, El-Daly M, Molnegren V, et al. Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma. J Gen Virol 2007; 88(Pt 5): 152631.
  • 38
    Frangeul L, Musset L, Cresta P, Cacoub P, Huraux JM, Lunel F. Hepatitis C virus genotypes and subtypes in patients with hepatitis C, with and without cryoglobulinemia. J Hepatol 1996; 25: 42732.
  • 39
    Gad A, Tanaka E, Matsumoto A, et al. Factors predisposing to the occurrence of cryoglobulinemia in two cohorts of Egyptian and Japanese patients with chronic hepatitis C infection: ethnic and genotypic influence. J Med Virol 2003; 70: 5949.
  • 40
    Remy AJ, Verdier E, Perney P, et al. Route of infection, liver histology and response to interferon in patients with chronic hepatitis caused by genotype 4 HCV infection in a Western country. J Hepatol 1998; 29: 169.
  • 41
    Zylberberg H, Chaix ML, Brechot C. Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-alpha. Ann Intern Med 2000; 132: 8456.
  • 42
    Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 95865.
  • 43
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 97582.
  • 44
    Thakeb F, Omar M, Bilharz T, Awady M, Isshak S. Randomized controlled trial of peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus-genotype 4 among Egyptian patients. Hepatology 2003; 38: 278A.
  • 45
    Shobokshi O, Serebour F, Skakni L, et al. Efficacy of pegylated (40 KDA) IFN alfa-2a (PEGASYS) plus ribavirin in the treatment of hepatitis C genotype 4 chronic active patients in Saudi Arabia. J Hepatol 2002; 36(Suppl. 1): 129.
  • 46
    Esmat G, Mohamed MK, Abdel Hamid M, et al. The impact of steatosis on baseline characteristic and end of treatment response for chronic hepatitis (C) genotype 4 patients treated with interferon. J Hepatol 2003; 38(Suppl. 2): 139.
  • 47
    Alfaleh FZ, Hadad Q, Khuroo MS, et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver Int 2004; 24: 56874.
  • 48
    Diago M, Hadziayannus S, Bodenheimer H Jr, et al. Optimized virological response in genotype 4 chrnoic hepatitis C patients treated with peginterferon alfa-2a (PEGASYS) in combination with ribavirin (RBV). AASLD 2002; 36: 364A.
  • 49
    Kamal SM, El Tawil AA, Nakano T, et al. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005; 54: 85866.
  • 50
    El-Zayadi AR, Attia M, Barakat EM, et al. Response of hepatitis C genotype-4 naive patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study. Am J Gastroenterol 2005; 100: 244752.
    Direct Link:
  • 51
    Korba BE, Montero AB, Farrar K, et al. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res 2008; 77: 5663.
  • 52
    Rossignol JF, Kabil SM, El-Gohary Y, Elfert A, Keeffe EB. Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther 2008; 28: 57480.
  • 53
    Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 2009; 136: 85662.
  • 54
    Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195206.
  • 55
    Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 240516.
  • 56
    Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 120717.
  • 57
    Benhamou A, Moussalli J, Ratziu V, et al. Activity of Telaprevir Monotherapy or in Combination with Pegintgerferon-Alfa-2a and Rib avirin in Treatment-Naive Genotype 4 Hepatitis-C Patients: final Results of Study c210. Gastroenterology and Hepatology 2011; 7(Suppl. 1): 1.
  • 58
    Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006; 131: 9971002.
  • 59
    Hassanein T, Nelson D, Lawitz E, et al. PSI-7977 with PEG/RBV elicits rapid declines in HCV RNA in patients with HCV GT-4 and GT-6. Poster Presentation at HEPDart 2011.
  • 60
    Flisiak R, Feinman SV, Jablkowski M, et al. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 2009; 49: 14608.
  • 61
    Hezode C, Hirschfield GM, Ghesquiere W, et al. Daclatasvir (BMS-79052), An NS5A replication complex inhibitor, combined with peginterferon-alfa-2a and ribavirin in treatment-naive HCV genotype 1 or 4 subjects: phase 2B AI444010 study interim week 24 results. Hep Intl 2012; 6: 67309.
  • 62
    Hezode C, Hirschfield G, Ghesquiere W, et al. Daclatasvir (DCV;BMS-790052), and NS5A replication complex inhibitor, combined with peginterferon-alfa-2B and ribavirin in treatment-naive HCV genotype 1 or 4 subjects: phase 2B command-1 study interim week 24 results. Hepatology 2011; 54(S1): 54A127A.
  • 63
    Hezode C, Hirschfield G, Ghesquiere W, et al. Daclatasvir (BMS-790052), A NS5A replication complex inhibitor, combined with peginterferon-alfa-2a and ribavirin in treatment-naive HCV genotype 1 or 4 subjects: phase 2b AI444010 study interim week 24 results. Hep Intl 2012; 6: 167.
  • 64
    Zeuzem S, Arora S, Bacon B, et al. 1360 Pegylated interferon-lambda pegifn-λ) shows superior viral response with improved safety and tolerability versus pegifnα-2A in hcv patients (Gl/2/3/4): emerge phase iib through week 12. J Hepatol 2011; 54(Suppl. 1): S5389.
  • 65
    Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection. N Engl J Med 2013; 368: 187887.
  • 66
    Smuts HE, Kannemeyer J. Genotyping of hepatitis C virus in South Africa. J Clin Microbiol 1995; 33: 167981.
  • 67
    van Doorn LJ, Kleter GE, Stuyver L, et al. Sequence analysis of hepatitis C virus genotypes 1 to 5 reveals multiple novel subtypes in the Benelux countries. J Gen Virol 1995; 76(Pt 7): 18716.
  • 68
    Henquell C, Cartau C, Abergel A, et al. High prevalence of hepatitis C virus type 5 in central France evidenced by a prospective study from 1996 to 2002. J Clin Microbiol 2004; 42: 30305.
  • 69
    Martinot-Peignoux M, Roudot-Thoraval F, Mendel I, et al. Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP. J Viral Hepat 1999; 6: 43543.
  • 70
    Legrand-Abravanel F, Sandres-Saune K, Barange K, et al. Hepatitis C virus genotype 5: epidemiological characteristics and sensitivity to combination therapy with interferon-alpha plus ribavirin. J Infect Dis 2004; 189: 1397400.
  • 71
    Abergel A, Ughetto S, Dubost S, et al. The epidemiology and virology of hepatitis C virus genotype 5 in central France. Aliment Pharmacol Ther 2007; 26: 143746.
  • 72
    Antaki N, Haddad M, Kebbewar K, et al. The unexpected discovery of a focus of hepatitis C virus genotype 5 in a Syrian province. Epidemiol Infect 2009; 137: 7984.
  • 73
    Jover R, Perez-Serra J, de Vera F, et al. Infection by genotype 5a of HCV in a district of southeast Spain. Am J Gastroenterol 2001; 96: 30423.
    Direct Link:
  • 74
    Karatapanis S, Tsoplou P, Papastergiou V, et al. Hepatitis C virus genotyping in Greece: unexpected high prevalence of genotype 5a in a Greek island. J Med Virol 2012; 84: 2238.
  • 75
    Bonny C, Fontaine H, Poynard T, et al. Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study. Aliment Pharmacol Ther 2006; 24: 593600.
  • 76
    Antaki N, Bibert S, Kebbewar K, et al. IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5. Gut 2012; 61: 16401.
  • 77
    Mauss S, Berger F, Vogel M, et al. Treatment results of chronic hepatitis C genotype 5 and 6 infections in Germany. Z Gastroenterol 2012; 50: 4414.
  • 78
    D'Heygere F, George C, Van Vlierberghe H, et al. Efficacy of interferon-based antiviral therapy in patients with chronic hepatitis C infected with genotype 5: a meta-analysis of two large prospective clinical trials. J Med Virol 2011; 83: 8159.
  • 79
    Antaki N, Hermes A, Hadad M, et al. Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5. J Viral Hepat 2008; 15: 3836.
  • 80
    Chinchai T, Labout J, Noppornpanth S, et al. Comparative study of different methods to genotype hepatitis C virus type 6 variants. J Virol Methods 2003; 109: 195201.
  • 81
    Dev AT, McCaw R, Sundararajan V, Bowden S, Sievert W. Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology 2002; 36: 125965.
  • 82
    Bouchardeau F, Cantaloube JF, Chevaliez S, et al. Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA HCV assay. J Clin Microbiol 2007; 45: 11405.
  • 83
    Verbeeck J, Stanley MJ, Shieh J, et al. Evaluation of Versant hepatitis C virus genotype assay (LiPA) 2.0. J Clin Microbiol 2008; 46: 19016.
  • 84
    Simmonds P, Mellor J, Sakuldamrongpanich T, et al. Evolutionary analysis of variants of hepatitis C virus found in South-East Asia: comparison with classifications based upon sequence similarity. In: J Gen Virol, 1996; 301324.
  • 85
    Sugiyama K, Kato N, Nakazawa T, et al. Novel genotypes of hepatitis C virus in Thailand. J Gen Virol 1995; 76(Pt 9): 23237.
  • 86
    Tokita H, Okamoto H, Tsuda F, et al. Hepatitis C virus variants from Vietnam are classifiable into the seventh, eighth, and ninth major genetic groups. Proc Natl Acad Sci USA 1994; 91: 110226.
  • 87
    Mellor J, Walsh EA, Prescott LE, et al. Survey of type 6 group variants of hepatitis C virus in Southeast Asia by using a core-based genotyping assay. J Clin Microbiol 1996; 34: 41723.
  • 88
    Lao W. Prevalence of genotype 6 chronic hepatitis C infection in Hong Kong. J Gastroenterol Hepatol 2002; 17: A142.
  • 89
    Lu L, Nakano T, He Y, Robertson BH, Hagedorn CH. Predominance of closely related HCV subtye 1B isolates throughout China and existence of new genotype 6 variants in Southern China. Hepatology 2004; 4(Suppl. 1): 413A.
  • 90
    Tokita H, Okamoto H, Iizuka H, et al. Hepatitis C virus variants from Jakarta, Indonesia classifiable into novel genotypes in the second (2e and 2f), tenth (10a) and eleventh (11a) genetic groups. J Gen Virol 1996; 77(Pt 2): 293301.
  • 91
    Adams NJ, Chamberlain RW, Taylor LA, et al. Complete coding sequence of hepatitis C virus genotype 6a. Biochem Biophys Res Commun 1997; 234: 3936.
  • 92
    Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 96273.
  • 93
    Laboratories LAN. Available at: http://hcv.lanl.gov/content/sequence/HCV/classification/genotable.html. Accessed September 2, 2012.
  • 94
    Li C, Lu L, Zhang X, Murphy D. Entire genome sequences of two new HCV subtypes, 6r and 6s, and characterization of unique HVR1 variation patterns within genotype 6. J Viral Hepat 2009; 16: 40617.
  • 95
    Katayama Y, Barzaga NG, Alipio A, et al. Genotype analysis of hepatitis C virus among blood donors and inmates in Metro Manila, The Philippines. Microbiol Immunol 1996; 40: 5259.
  • 96
    Nguyen NH, Vutien P, Trinh HN, et al. Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans. Hepatol Int 2010; 4: 5239.
  • 97
    Nguyen LH, Nguyen MH. Systematic review: Asian patients with chronic hepatitis C infection. Aliment Pharmacol Ther 2013; 37: 92136.
  • 98
    Lam KD, Trinh HN, Do ST, et al. Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6. Hepatology 2010; 52: 157380.
  • 99
    Thu Thuy PT, Bunchorntavakul C, Tan Dat H, Rajender Reddy K. A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C. J Hepatol 2012; 56: 10128.
  • 100
    Hui CK, Yuen MF, Sablon E, Chan AO, Wong BC, Lai CL. Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1. J Infect Dis 2003; 187: 10714.
  • 101
    Cheng JT, Hsien C, Sun HE, Tong MJ. The emerging importance of chronic hepatitis C infection in Asian Americans. Am J Gastroenterol 2006; 101: 273743.
    Direct Link:
  • 102
    Fung J, Lai CL, Hung I, et al. Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. J Infect Dis 2008; 198: 80812.
  • 103
    Nguyen MH, Trinh HN, Garcia R, Nguyen G, Lam KD, Keeffe EB. Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin. Am J Gastroenterol 2008; 103: 11315.
    Direct Link:
  • 104
    Seto WK, Lai CL, Fung J, et al. Natural history of chronic hepatitis C: genotype 1 versus genotype 6. J Hepatol 2010; 53: 4448.
  • 105
    Tsang OT, Zee JS, Chan JM, et al. Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1. J Gastroenterol Hepatol 2010; 25: 76671.
  • 106
    Chao DT, Abe K, Nguyen MH. Systematic review: epidemiology of hepatitis C genotype 6 and its management. Aliment Pharmacol Ther 2011; 34: 28696.